Colonis, founded 18 years ago as one pharmacist’s vision to improve the lives of patients, is still prioritising the identification of unique opportunities and repurposing medicines to meet unmet patient and clinical needs. Following acquisition by the Clinigen Group in 2017, Colonis will now operate as a standalone business unit which has resulted in a new identity for the company.  

In establishing this new identity, it was important to highlight that Colonis is a catalyst for change, identifying products to be repurposed, and developing them further to meet the needs of patients whose treatment options may be limited.

“Now operating as a standalone business, Colonis will focus on a long-term growth strategy to identify new product development opportunities along with the expansion of our portfolio in global markets. Our new identity is an important step in sharing not only the success we have achieved so far, but how we want to take our business forward in the future. Our new website creates a professional yet personal space to tell our story and give a clear and strong understanding of who Colonis is.”  Andy Trouton, Managing Director

Please contact us at info@colonis.co.uk for any enquiries you may have.

GB-CPL-0-022

September 2023